- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03566173
Association Between Nonalcoholic Fatty Liver Disease and Acute Pancreatitis
Study Overview
Status
Detailed Description
Acute pancreatitis (AP) is a potentially lethal disease capable of wide clinical variation. Severe acute pancreatitis (SAP) is devastating, with a mortality rate ranging from 10% to as high as 85%. So it's important to identify severe patients which require aggressive early treatment and prolonged specialist care. There are a lot of multifactorial scorings and specific laboratory tests in predicting AP severity, such as Ranson's, Acute Physiology and Chronic Health Examination (APACHE)-II, serum Interleukin-6 (IL-6), and C-reactive protein (CRP) level. However, they have limitations in predicting outcomes of AP patients. The biochemical markers are not accurate enough. Ranson's scores were calculated after 48 hours of admission. Their practical utilization as predictors of severity is tough. Novel prognostic biomarker is needed to further develop for prognosis in AP patients.
Nonalcoholic fatty liver disease (NAFLD) refers to fat deposition and oxidative stress of free radicals in hepatocytes. NAFLD is the most common chronic liver disease worldwide. The prevalence averages 30% in developed countries, and estimated to be 10% in developing countries. Its presentation ranges from asymptomatic steatosis to fibrosis, and cirrhosis with 3-5%. It is evident clinically with increased risk of developing obesity, cardiovascular diseases (CVD), hyperlipidaemia, and type 2 diabetes mellitus (T2DM). Acting as an endocrine organ, the liver is the source of adipokines and inflammatory cytokines. Alterations in the production and secretion are increased in patients with NAFLD. It is strongly related to insulin resistance (IR) and metabolic disorders. Previous studies noted that NAFLD is closely related to severity of AP. CT scans are usually performed at admission to diagnose AP severity, which are also helpful to assess NAFLD. It could act as a valuable prognostic factor in AP patients and help to recognize potential severe patients.
However, no clear pathways could explain the association between NAFLD and AP at present. Besides, the data is scarce. More research will pay more attention to this topic. In this study, the investigators investigated the association between NAFLD and AP.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Ningbo, Zhejiang, China, 315010
- Ningbo NO.1 hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- diagnosed with AP
- age >18 years
Exclusion Criteria:
- an age of <18 years
- without complete data and CT scans
- previous splenectomy or hepatectomy
- a past history of AP
- an ambiguous pancreatic margin
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparisons of variables (age in years, BMI in kg/m2, pancreas attenuation in HU) on the basis of AP severity
Time Frame: the physical examination data in the year of 2017
|
Comparisons of variables on the basis of AP severity by one-way analysis of variance (ANOVA)
|
the physical examination data in the year of 2017
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Association between NAFLD and severity outcomes in AP patients
Time Frame: the physical examination data in the year of 2017
|
Association between liver/spleen attenuation (L/S) ratio in Hounsfield units (HU) and severity outcomes in AP patients by Cox regression analysis
|
the physical examination data in the year of 2017
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Ningbo5
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nonalcoholic Fatty Liver Disease
-
Columbia UniversityThorne Research Inc.WithdrawnNASH - Nonalcoholic Steatohepatitis | NAFLD - Nonalcoholic Fatty Liver Disease
-
University of AarhusCompletedNASH - Nonalcoholic Steatohepatitis | NAFLD - Nonalcoholic Fatty Liver DiseaseDenmark
-
Merck Sharp & Dohme LLCRecruitingNon-alcoholic Fatty Liver Disease | NAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis | Fatty Liver, NonalcoholicCanada, United States, Puerto Rico, Israel, Japan, Korea, Republic of, Taiwan, Spain, Chile, France, Italy, Hungary, Switzerland, Belgium, China, Singapore, Czechia, Portugal, Austria, United Kingdom, Thailand, Hong Kong, Turkey
-
Columbia UniversityPfizerWithdrawnNASH (Nonalcoholic Steatohepatitis) | NAFLD (Nonalcoholic Fatty Liver Disease)
-
AdventHealth Translational Research InstituteCompletedNASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver DiseaseUnited States
-
AstraZenecaCompletedNon-alcoholic Fatty Liver Disease | NAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis | NASH | Fatty Liver, NonalcoholicUnited States
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Assistance Publique - Hôpitaux de ParisCompletedNonalcoholic Fatty Liver Disease (NAFLD)France
-
Massachusetts General HospitalCompletedNonalcoholic Fatty Liver Disease (NAFLD)United States
-
Miriam Vos, MDImmuron Ltd.; Advanced MR Analytics ABCompletedNonalcoholic Fatty Liver Disease (NAFLD)United States